PT  - JOURNAL ARTICLE
AU  - Gelaw, Negalgn Byadgie
AU  - Muche, Achenef Asmamaw
AU  - Alem, Adugnaw Zeleke
AU  - Gebi, Nebiyu Bekele
AU  - Chekol, Yazachew Moges
AU  - Tesfie, Tigabu Kidie
AU  - Tebeje, Tsion Mulat
TI  - Prediction of the risk for diabetic neuropathy among diabetes mellitus patients at selected referral hospitals, in Amhara regional state Northwest Ethiopia, January, 2005- December 2021; Development and validation of risk prediction model
AID  - 10.1101/2022.10.10.22280924
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.10.10.22280924
4099  - http://medrxiv.org/content/early/2022/10/11/2022.10.10.22280924.short
4100  - http://medrxiv.org/content/early/2022/10/11/2022.10.10.22280924.full
AB  - Background Diabetic neuropathy is the most common complication in both Type-1 and Type-2 DM patients with more than one half of all patients developing nerve dysfunction in their lifetime. Although, risk prediction model was developed for diabetic neuropathy in developed countries, It is not applicable in clinical practice, due to poor data, methodological problems, inappropriately analyzed and reported. To date, no risk prediction model developed for diabetic neuropathy among DM in Ethiopia, Therefore, this study aimed prediction the risk of diabetic neuropathy among DM patients, used for guiding in clinical decision making for cliniciansObjective Prediction of the risk for diabetic neuropathy among diabetes mellitus patients, in selected referral hospitals, Amhara regional state, northwest Ethiopia,2022Methods A retrospective follow up study was conducted with a total of 808 DM patients were enrolled from January 1,2005 to December 30,2021 at two selected referral hospitals in Amhara regional state. Multi-stage sampling techniques were used and the data was collected by checklist from medical records by Kobo collect and exported to STATA version-17 for analysis. Lasso method were used to select predictors and entered to multivariable logistic regression with P-value<0.05 was used for nomogram development. Model performance was assessed by AUC and calibration plot. Internal validation was done through bootstrapping method and decision curve analysis was performed to evaluate net benefit of modelResults The incidence proportion of diabetic neuropathy among DM patients was 21.29 %(95% CI; 18.59, 24.25).In multivariable logistic regression glycemic control, other comorbidities, physical activity, hypertension, alcohol drinking, type of treatment, white blood cells and red blood cells count were statistically significant. Nomogram was developed, has discriminating power AUC; 73.2 %(95% CI; 69.0%, 77.3%) and calibration test (P-value = 0.45). It was internally validated by bootstrapping method with discrimination performance 71.7(95% CI; 67.2 %, 75.9%).It had less optimism coefficient (0.015).To make nomogram accessible, mobile based tool were developed. In machine learning, classification and regression tree has discriminating performance of 70.2 %(95 % CI; 65.8%, 74.6%).The model had high net benefit at different threshold probabilities in both nomogram and classification and regression tree.Conclusion The developed nomogram and decision tree, has good level of accuracy and well calibration, easily individualized prediction of diabetic neuropathy. Both models had added net benefit in clinical practice and to be clinically applicable mobile based tool were developed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funder Mizan Aman college of health sciences, Ethiopia with 25,000 Ethiopian birr for academic purpose but had no role in study design, data collection and analysis, decision to publish or preparation of manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Ethical approval found in supplementary file S-3 obtained at university of Gondar Ethical review boardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.AUCArea under the CurveBMIBody Mass IndexCIConfidence IntervalCRTClassification and Regression TreeDBPDiastolic Blood PressureDCADecision Curve AnalysisDMDiabetes MellitusDPNDiabetic Peripheral NeuropathyFBGFasting Blood GlucoseHDLHigh Density Lip-ProteinHbA1cGlycated Hemoglobin A1 cICTInformation Communication TechnologyIDFInternational Diabetes FederationIQRInter Quartile RangeLASSOLeast Absolute Shrinkage and Selection OperatorLDLLow Density Lip-ProteinLR+Log Likelihood Ratio PositiveLR_Log Likelihood Ratio NegativeMNSIMichigan Neuropathy Screening InstrumentNPVNegative Predictive ValuePBGPost Bradial GlucosePPVPositive Predictive ValueRBCRed Blood CellsROCReceiver Operating CharacteristicsSBPSystolic Blood PressureSRMASystematic Review and Meta-AnalysisT1DMType-1 Diabetes Mellitus T2DM;Type-2 Diabetes MellitusTCTotal CholesterolTGTotal TriglycerideUOGUniversity of GondarWBCWhite Blood Cells